The Patent Finder

Terms ending in 2031

Ambrx, Inc.

Every in-force patent on Ambrx, Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,452,222Nucleic Acids Encoding Modified Relaxin Polypeptides
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 10,253,083Therapeutic Uses of Modified Relaxin Polypeptides
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 10,702,588Modified Relaxin Polypeptides Comprising A Non-Naturally Encoded Amino Acid In The A Chain
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 10,751,391Methods of Treatment Using Modified Relaxin Polypeptides Comprising a Non-Naturally Encoded Amino Acid
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 11,786,578Modified Relaxin Polypeptides and Their Uses
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
US 9,567,386Therapeutic Uses of Modified Relaxin Polypeptides
In force
 · High confidence
Ambrx, Inc.In forceHigh confidence
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited